165 related articles for article (PubMed ID: 10566011)
1. Marimastat. BB 2516, TA 2516.
Drugs R D; 1999 Feb; 1(2):146-9. PubMed ID: 10566011
[No Abstract] [Full Text] [Related]
2. AG 3340.
Drugs R D; 1999 Feb; 1(2):137-8. PubMed ID: 10566007
[No Abstract] [Full Text] [Related]
3. CGS 27023A. CDG 27023A.
Drugs R D; 1999 Feb; 1(2):144-5. PubMed ID: 10566010
[No Abstract] [Full Text] [Related]
4. AE 941--Neovastat.
Drugs R D; 1999 Feb; 1(2):135-6. PubMed ID: 10566006
[No Abstract] [Full Text] [Related]
5. BAY12-9566. BAY 12 9566, BAY12 9566.
Drugs R D; 1999 Feb; 1(2):142-3. PubMed ID: 10566009
[No Abstract] [Full Text] [Related]
6. Batimastat. BB 94, collagenase inhibitors-1.
Drugs R D; 1999 Feb; 1(2):139-41. PubMed ID: 10566008
[No Abstract] [Full Text] [Related]
7. Omapatrilat.
Drugs R D; 1999 Apr; 1(4):350-1. PubMed ID: 10566062
[No Abstract] [Full Text] [Related]
8. Marimastat: BB 2516, TA 2516.
Drugs R D; 2003; 4(3):198-203. PubMed ID: 12757409
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat.
Rasmussen HS; McCann PP
Pharmacol Ther; 1997; 75(1):69-75. PubMed ID: 9364582
[TBL] [Abstract][Full Text] [Related]
10. Endopeptidase inhibitors. Summary and table.
Coleman SG; Duff R
Drugs R D; 1999 Apr; 1(4):339-40. PubMed ID: 10566057
[No Abstract] [Full Text] [Related]
11. Marimastat in patients with advanced pancreatic cancer: a dose-finding study.
Rosemurgy A; Harris J; Langleben A; Casper E; Goode S; Rasmussen H
Am J Clin Oncol; 1999 Jun; 22(3):247-52. PubMed ID: 10362330
[TBL] [Abstract][Full Text] [Related]
12. Candoxatrilat. UK 73967.
Drugs R D; 1999 Apr; 1(4):341-2. PubMed ID: 10566058
[No Abstract] [Full Text] [Related]
13. SCH 42495.
Drugs R D; 1999 Apr; 1(4):354-6. PubMed ID: 10566064
[No Abstract] [Full Text] [Related]
14. A phase II trial of marimastat in advanced pancreatic cancer.
Evans JD; Stark A; Johnson CD; Daniel F; Carmichael J; Buckels J; Imrie CW; Brown P; Neoptolemos JP
Br J Cancer; 2001 Dec; 85(12):1865-70. PubMed ID: 11747327
[TBL] [Abstract][Full Text] [Related]
15. Marimastat (BB2516): current status of development.
Steward WP
Cancer Chemother Pharmacol; 1999; 43 Suppl():S56-60. PubMed ID: 10357560
[TBL] [Abstract][Full Text] [Related]
16. Ecadotril. (S)-acetorphan, sinorphan.
Drugs R D; 1999 Apr; 1(4):343-5. PubMed ID: 10566059
[No Abstract] [Full Text] [Related]
17. Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer.
Moore M; Maroun J; Robert F; Natale R; Neidhart J; Dallaire B; Sisk R; Gyves J
Invest New Drugs; 1993 Feb; 11(1):61-5. PubMed ID: 8349438
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloprotease inhibitors. Summary and Table.
Coleman SG
Drugs R D; 1999 Feb; 1(2):131-4. PubMed ID: 10566005
[No Abstract] [Full Text] [Related]
19. [Antitumor effect of a matrix metalloproteinase inhibitor, TA-2516 (Marimastat), on a nude mouse model of intraperitoneal seeding of stomach cancer].
Kimata D; Otani Y; Kubota T; Igarashi N; Yokoyama T; Wada N; Kumai K; Okada Y; Kameyama K; Kitajima M
Nihon Geka Gakkai Zasshi; 1999 May; 100(5):363. PubMed ID: 10475795
[No Abstract] [Full Text] [Related]
20. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
